| Date | Time | Source | Headline | Symbol | Company |
| 05/11/2023 | 2:00AM | UK Regulatory | MaxCyte, Inc. First Quarter Financial Results | LSE:MXCT | Maxcyte Inc |
| 05/10/2023 | 1:35AM | Alliance News |  GET READY: Compass, Harbour Energy, JD Wetherspoon, TUI at 0700 BST | LSE:MXCT | Maxcyte Inc |
| 05/09/2023 | 2:00AM | UK Regulatory | MaxCyte, Inc. Exercise of options and PDMR dealing | LSE:MXCT | Maxcyte Inc |
| 05/04/2023 | 12:26PM | Alliance News | IN BRIEF: MaxCyte signs strategic platform license with Walking Fish | LSE:MXCT | Maxcyte Inc |
| 05/04/2023 | 8:05AM | UK Regulatory | MaxCyte, Inc. Signing of Strategic Platform License | LSE:MXCT | Maxcyte Inc |
| 05/03/2023 | 11:22AM | UK Regulatory | MaxCyte, Inc. Director/PDMR Shareholding | LSE:MXCT | Maxcyte Inc |
| 04/13/2023 | 2:00AM | UK Regulatory | MaxCyte, Inc. Notice of First Quarter 2023 Financial Results | LSE:MXCT | Maxcyte Inc |
| 03/30/2023 | 11:03AM | Alliance News | IN BRIEF: MaxCyte Chair Richard Douglas buys USD350,000 in shares | LSE:MXCT | Maxcyte Inc |
| 03/30/2023 | 7:46AM | UK Regulatory | MaxCyte, Inc. Director/PDMR Shareholding | LSE:MXCT | Maxcyte Inc |
| 03/28/2023 | 5:44AM | Alliance News | MaxCyte appoints new chief financial officer, effective immediately | LSE:MXCT | Maxcyte Inc |
| 03/28/2023 | 2:00AM | UK Regulatory | MaxCyte, Inc. Appointment of Chief Financial Officer | LSE:MXCT | Maxcyte Inc |
| 03/22/2023 | 3:00AM | UK Regulatory | MaxCyte, Inc. Grant of Options and PDMR Dealing | LSE:MXCT | Maxcyte Inc |
| 03/16/2023 | 8:20AM | Alliance News | MaxCyte revenue up as growth expected in 2023; net loss widens | LSE:MXCT | Maxcyte Inc |
| 03/16/2023 | 3:01AM | UK Regulatory | MaxCyte, Inc. Filing of Form 10-K | LSE:MXCT | Maxcyte Inc |
| 03/16/2023 | 3:00AM | UK Regulatory | MaxCyte, Inc. 2022 Full Year Results | LSE:MXCT | Maxcyte Inc |
| 03/08/2023 | 1:14PM | Alliance News | IN BRIEF: MaxCyte names members of new scientific advisory board | LSE:MXCT | Maxcyte Inc |
| 03/08/2023 | 8:00AM | UK Regulatory | MaxCyte, Inc. Establishment of New Scientific Advisory Board | LSE:MXCT | Maxcyte Inc |
| 03/07/2023 | 5:51AM | Alliance News | MaxCyte revenue grows in 2022, expects further revenue climb in 2023 | LSE:MXCT | Maxcyte Inc |
| 03/07/2023 | 2:00AM | UK Regulatory | MaxCyte, Inc. Preliminary Unaudited Q4 &FY 2022 Revenue Results | LSE:MXCT | Maxcyte Inc |
| 03/06/2023 | 4:05PM | PR Newswire (US) | MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue Results and Provides 2023 Revenue Guidance | LSE:MXCT | Maxcyte Inc |
| 02/06/2023 | 10:40AM | UK Regulatory | MaxCyte, Inc. Director/PDMR Shareholding | LSE:MXCT | Maxcyte Inc |
| 02/02/2023 | 2:00AM | UK Regulatory | MaxCyte, Inc. Notice of Results | LSE:MXCT | Maxcyte Inc |
| 01/30/2023 | 2:00AM | UK Regulatory | MaxCyte, Inc. Exercise of options and PDMR dealing | LSE:MXCT | Maxcyte Inc |
| 01/04/2023 | 3:56AM | Alliance News | MaxCyte signs strategic platform licence with Catamaran Bio | LSE:MXCT | Maxcyte Inc |
| 01/04/2023 | 2:00AM | UK Regulatory | MaxCyte, Inc. Signing of Strategic Platform License | LSE:MXCT | Maxcyte Inc |
| 01/03/2023 | 4:05PM | PR Newswire (US) | MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs | LSE:MXCT | Maxcyte Inc |
| 12/05/2022 | 4:49PM | Alliance News | TRADING UPDATES: MaxCyte in deal; Angus to resume Saltfleetby drilling | LSE:MXCT | Maxcyte Inc |
| 12/05/2022 | 2:00AM | UK Regulatory | MaxCyte, Inc. Signing of Strategic Platform License | LSE:MXCT | Maxcyte Inc |
| 12/02/2022 | 12:22PM | UK Regulatory | MaxCyte, Inc. Total Voting Rights | LSE:MXCT | Maxcyte Inc |
| 12/01/2022 | 2:00AM | UK Regulatory | MaxCyte, Inc. Non-Executive Director Appointment | LSE:MXCT | Maxcyte Inc |